View Older Stories

Sep 3, 2026 06:52AM Ultragenyx Pharma (RARE) PT Lowered to $37 at Canaccord

Sep 3, 2026 06:35AM Ultragenyx Pharma (RARE) PT Lowered to $33 at Cantor Fitzgerald

Sep 3, 2026 06:22AM Ultragenyx Pharma (RARE) PT Lowered to $18 at Wells Fargo, Downgrades to Equalweight

Sep 3, 2026 06:01AM Ultragenyx Pharma (RARE) call put ratio 1 call to 3 puts into Phase 3 results

Sep 3, 2026 04:10AM JPMorgan Downgrades Ultragenyx Pharma (RARE) to Neutral

Sep 3, 2026 04:09AM Baird Downgrades Ultragenyx Pharma (RARE) to Neutral

Sep 3, 2026 02:36AM Evercore ISI Downgrades Ultragenyx Pharma (RARE) to In Line

Sep 3, 2026 02:35AM Morgan Stanley Reiterates Overweight Rating on Belimo Holding AG (BEAN:SW) (BLHWF)

Sep 2, 2026 04:26PM After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE

Sep 1, 2026 04:06PM Ultragenyx publishes 96-week phase 3 data for GSDIa gene therapy

Aug 28, 2026 06:30AM Ultragenyx Pharma (RARE) PT Raised to $50 at Wells Fargo

Aug 20, 2026 06:56AM H.C. Wainwright Reiterates Buy Rating on Ultragenyx Pharma (RARE)

Aug 20, 2026 06:50AM Ultragenyx Pharma (RARE) PT Raised to $83 at Canaccord

Aug 20, 2026 05:04AM Citi raises Ultragenyx price target to $58 after FDA approval

Aug 10, 2026 06:43AM H.C. Wainwright Reiterates Buy Rating on Ultragenyx Pharma (RARE)

Aug 5, 2026 01:02AM Ultragenyx Pharma (RARE) Tops Q2 EPS by 32c ; Offers Guidance

Aug 4, 2026 06:54AM Ultragenyx Pharma (RARE) PT Lowered to $35 at Guggenheim

May 21, 2026 06:36AM Ultragenyx Pharma (RARE) PT Raised to $96 at Cantor Fitzgerald

May 5, 2026 04:34PM Ultragenyx Pharma (RARE) Misses Q1 EPS by 38c, provides guidance

Apr 2, 2026 12:00PM Morgan Stanley on Ultragenyx Pharma (RARE): BLA submission acceptance removes key overhang

Apr 2, 2026 10:46AM Leerink Partners on Ultragenyx Pharma (RARE): FDA BLA acceptance positions co for two approvals, $150M oppty

Apr 2, 2026 08:31AM FDA accepts Ultragenyx resubmission for rare disease gene therapy UX111

Mar 30, 2026 08:32AM Ultragenyx receives FDA clearance for GNE myopathy drug trial

Mar 24, 2026 02:32AM Goldman Sachs Downgrades Ultragenyx Pharma (RARE) to Neutral

Mar 12, 2026 11:55AM BofA Securities Reiterates Buy Rating on Ultragenyx Pharma (RARE): "current valuation undervalues the pipeline opportunity"

Mar 12, 2026 11:55AM BofA Securities Reiterates Buy Rating on Ultragenyx Pharma (RARE): "current valuation undervalues the pipeline opportunity"

Mar 12, 2026 10:39AM Leerink Partners Reiterates Outperform Rating on Ultragenyx Pharma (RARE): "encouraged by this clinical win"

Feb 18, 2026 06:44AM Ultragenyx Pharma (RARE) PT Lowered to $79 at Canaccord Genuity

Feb 12, 2026 04:30PM Ultragenyx Pharma (RARE) Misses Q4 EPS by 14c, provides guidance

Feb 3, 2026 06:44AM H.C. Wainwright Reiterates Buy Rating on Ultragenyx Pharma (RARE)

Jan 30, 2026 08:31AM Ultragenyx resubmits gene therapy application for rare brain disease

Jan 12, 2026 07:31AM Ultragenyx reports preliminary 2025 revenue of $672-674 million

Jan 6, 2026 06:42AM Ultragenyx Pharma (RARE) PT Lowered to $60 at H.C. Wainwright

Jan 5, 2026 07:35AM Ultragenyx Pharma (RARE) PT Lowered to $52 at Guggenheim

Jan 2, 2026 05:25AM Ultragenyx Pharma (RARE) PT Lowered to $58 at BofA Securities

Dec 31, 2025 09:23AM Leerink on Ultragenyx Pharma (RARE): 'DTX401 Rolling BLA Submitted, Setting Up Launch for Underappreciated Program'

Dec 30, 2025 04:06PM Ultragenyx completes gene therapy application for rare metabolic disease

Dec 30, 2025 04:58AM Ultragenyx Pharma (RARE) PT Lowered to $45 at Wells Fargo

Dec 30, 2025 04:55AM Ultragenyx Pharma (RARE) PT Lowered to $63 at Jefferies

Dec 30, 2025 04:54AM Jefferies Downgrades Mereo BipPharma Group (MREO) to Hold

Dec 30, 2025 02:03AM Ultragenyx Pharma (RARE) PT Lowered to $71 at Goldman Sachs

Dec 29, 2025 03:27PM Ultragenyx Pharma (RARE) PT Lowered to $70 at Leerink Partners

Dec 29, 2025 03:27PM Mereo BipPharma Group (MREO) PT Lowered to $2 at Leerink Partners

Dec 29, 2025 01:50PM TD Cowen Reiterates Buy Rating on Ultragenyx Pharma (RARE)

Dec 29, 2025 01:11PM LifeSci Capital Downgrades Mereo BipPharma Group (MREO) to Market Perform

Dec 29, 2025 12:48PM Ultragenyx Pharma (RARE) PT Lowered to $47 at Baird

Dec 29, 2025 12:12PM Ultragenyx Pharma (RARE) PT Lowered to $50 (from $103) at Citi

Dec 29, 2025 12:04PM William Blair Reiterates Outperform Rating on Ultragenyx Pharma (RARE)

Dec 29, 2025 12:04PM Leerink Partners Reiterates Outperform Rating on Ultragenyx Pharma (RARE)

Dec 29, 2025 12:03PM Morgan Stanley Reiterates Overweight Rating on Ultragenyx Pharma (RARE)

View Older Stories